Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)…
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple…
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable…
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage DiagnosisBOSTON--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data…
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage DiagnosisBOSTON--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data…
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May…
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of…
STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor Collaboration enables…
Research shows ability to surface real-world, regimen-specific symptom trends and highlight potential in-class differences using the Canopy Remote Therapeutic Monitoring…